Anti-VEGF Cancer Therapy in Nephrology Practice
Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established....
Saved in:
Main Author: | Hassan Izzedine |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | International Journal of Nephrology |
Online Access: | http://dx.doi.org/10.1155/2014/143426 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-VEGF therapy for proliferative diabetic retinopathy: translating research evidence into clinical practice
by: E.A. Abdulaeva, et al.
Published: (2020-06-01) -
Anti-VEGF-therapy for pseudoxanthoma elasticum (case reports)
by: A.D. Chuprov, et al.
Published: (2023-08-01) -
VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy
by: Caroline Hilmi, et al.
Published: (2012-01-01) -
Effectiveness and tolerability of the combined use of anti-VEGF agents in clinical practice
by: A.V. Kuroyedov, et al.
Published: (2020-11-01) -
Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians
by: Pearse A. Keane, et al.
Published: (2012-01-01)